Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All
i

superseded


Update on recommendations for use of herpes zoster vaccine

Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years

  • Published Date:

    November 11, 2011

  • Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(44):1528.
  • Language:
    English
Filetype[HTM]


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Alternative Title:
    MMWR. Morbidity and mortality weekly report
  • Description:
    Herpes zoster vaccine (Zostavax, Merck & Co., Inc.) was licensed and recommended in 2006 for prevention of herpes zoster among adults aged 60 years and older. In March 2011, the Food and Drug Administration (FDA) approved the use of Zostavax in adults aged 50 through 59 years. In June 2011, the Advisory Committee on Immunization Practices (ACIP) declined to recommend the vaccine for adults aged 50 through 59 years and reaffirmed its current recommendation that herpes zoster vaccine be routinely recommended for adults aged 60 years and older.
  • Subject:
  • Pubmed ID:
    22071592
  • Document Type:
    Journal Article
  • Name as Subject:
    United States. Food and Drug Administration.
  • Place as Subject:
    United States
  • Collection(s):
    Guidelines and Recommendations
  • Main Document Checksum:
  • File Type:
  • Supporting Files:
    No Additional Files
No Related Documents.

You May Also Like:

  1. Filetype[JPEG - 624.30 KB]
    Corporate Authors:
    National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
    Published Date:
    June 20, 2018
    Description:
    Get the second dose 2-6 mnths after the first dose.takes-2-sea-1200x600.jpg
    File Type:
    Filetype[JPEG - 624.30 KB]
    File Type:
    Filetype[JPEG - 624.30 KB]
  2. Filetype[PDF - 70.38 KB]
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    May 2016
    Description:
    Addressing common questions about shingles vaccination for adultsCS HCVG15-ADU-125 07/13/2016fs-shingles-hcp.pdf
    File Type:
    Filetype[PDF - 70.38 KB]
    File Type:
    Filetype[PDF - 70.38 KB]
  3. Filetype[JPEG - 744.82 KB]
    Corporate Authors:
    National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
    Published Date:
    June 20, 2018
    Description:
    Maka an appointment now to get your second dose;takes-2-kitchen-1200x600.jpg
    File Type:
    Filetype[JPEG - 744.82 KB]
    File Type:
    Filetype[JPEG - 744.82 KB]
  4. Filetype[PDF - 1.50 MB]
    Personal Author:
    Guo, Angela
    Corporate Authors:
    National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
    Conference Authors:
    United States. Advisory Committee on Immunization Practices. Meeting (2017 October 25-26 : Atlanta, GA)
    Published Date:
    11/15/2017
    Series:
    ACIP meeting Herpes Zoster Vaccine
    Description:
    Presentations October 2017 Day 1Publication date from document properties.zoster-02-guo.pdf
    File Type:
    Filetype[PDF - 1.50 MB]
    File Type:
    Filetype[PDF - 1.50 MB]
  5. Filetype[PDF - 621.23 KB]
    Personal Author:
    Belongia, Edward A.
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices. Zoster Working Group.
    Conference Authors:
    United States. Advisory Committee on Immunization Practices. Meeting (2015 June 24-25 : Atlanta, GA)
    Published Date:
    June 25, 2015
    Series:
    ACIP meeting Herpes Zoster Vaccine
    File Type:
    Filetype[PDF - 621.23 KB]
    File Type:
    Filetype[PDF - 621.23 KB]